FUEL FOR INNOVATION

Jennifer Barretta brings 25 years of human resources experience to HighCape Partners. She currently provides consulting expertise to HighCape portfolio companies in all aspects of human resource management and leadership development. Ms. Barretta most recently held the position of Vice President of Human Resources for Shire Regenerative Medicine from 2011 to 2012. Prior to that, Ms. Barretta served as Vice President of Human Resources for Advanced BioHealing from 2006 until its acquisition by Shire in 2011, where she led the human resources function through a period of tremendous maturity as the company grew from 8 to over 500 employees during her tenure. Prior to Advanced BioHealing, Ms. Barretta was at Genaissance Pharmaceuticals, Inc. until its merger with Clinical Data, Inc. in 2005. She holds a B.S. in Business Management from Syracuse University.

Dr. Ranjit Bindra is a physician-scientist at the Yale School of Medicine, the Harvey and Kate Cushing Professor of Therapeutic Radiology, and the Scientific Director of the Yale Brain Tumor Center. Clinically, he treats adult and pediatric primary CNS cancers, as well as brain metastases using radiosurgery.

Aside from his work as a physician and world-renowned research scientist at Yale, Dr. Bindra is also an active biotech entrepreneur. He has founded six companies based on work from his laboratory, including HighCape funded companies Cybrexa Therapeutics, Alphina Therapeutics and Modifi Biosciences, which was acquired by Merck in 2024.

Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.

Dr. Charles Hart brings over 35 years of research and development experience in the biotechnology field. Before joining HighCape as an Operating Partner, Dr. Hart held the position of Vice President of Research for Shire Regenerative Medicine from 2011 to 2013. Prior to joining Shire, Dr. Hart served as Vice President and Chief Scientific Officer at Advanced BioHealing from 2008 until its acquisition by Shire in 2011. From 2004 to 2008, he served as Vice President and Chief Scientific Officer at BioMimetic Therapeutics, a company focused on the development of products for the treatment of musculoskeletal injuries. Previous to that, he spent 21 years at ZymoGenetics, Inc., a biotechnology company focused on protein therapeutics, where he held a variety of leadership positions.

Dr. Hart has authored over 60 scientific publications and holds over 50 U.S. patents. He received his Ph.D. from the University of Washington, his M.S. from Oregon State University and his B.S. from the University of California at Davis.

Kevin Rakin is co-founder of HighCape Capital and brings more than 30 years of experience as an investor and executive in the life sciences industry. Prior to founding HighCape in 2013 he served as President of Shire Regenerative Medicine and prior to that role was Chairman and Chief Executive Officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011. Before that, he served as an executive-in-residence at Canaan Partners. Previously, he was a co-founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly traded pharmacogenomics company, until its merger with Clinical Data, Inc. in 2005. His Board memberships include Elutia (Chairman), Wellinks (Chairman), Cybrexa Therapeutics, Nyxoah SA, Quantum-Si, Alphina Therapeutics and CapeHaven.

He has previously served as a Board member for Modifi BioSciences (sold to Merck), Cheetah Medical (sold to Baxter), Collagen Matrix, TELA Bio, Histogenics Corp, Oramed Pharmaceuticals, Ipsogen SA, VionPharmaceuticals, OMRIX Biopharmaceuticals and Clinical Data. Mr. Rakin received an M.B.A. from Columbia University and B.Com (Hons) from the University of Cape Town, South Africa.

Dr. Carol Reed has over 20 years of experience in drug and device development in the areas of pulmonary diseases, psychiatry, cardiology, gastroenterology and infectious diseases, in addition to 10 years’ experience as a physician in the practice of pulmonary and critical care medicine. Prior to becoming an Operating Partner at HighCape, Dr. Reed was Chief Medical Officer and Executive Vice President at Clinical Data, Inc. from 2005 through 2011 where she was responsible for the development and approval by the U.S. Food and Drug Administration of the antidepressant VIIBRYD^®, and for the launch of DNA sequencing tests for cardiac genetic disorders including Long QT Syndrome.

Prior to this time, Dr. Reed was Vice President, Medical Affairs at Genaissance Pharmaceuticals. Dr. Reed earned an MD from the Rush Medical College in Chicago and an M.S. in Biology from the University of Illinois at Chicago. She is a Fellow of the American College of Physicians and the American College of Chest Physicians.

Based on her deep experience in pulmonology and drug development, Dr. Reed is a key scientific advisory to HighCape’s portfolio company, Wellinks.

Dean Tozer has more than 30 years of experience in the global healthcare industry with an established track record of successfully commercializing innovative Life Sciences products and technologies. Before joining HighCape, he served as Chief Commercial Officer and then President & Chief Executive Officer of Nuo Therapeutics. Prior to Nuo he was Vice President of Corporate Development for Shire Regenerative Medicine, which acquired Advanced BioHealing in 2011, where he was Senior Vice President. Prior to these roles, he spent more than 10 years in the global pharmaceutical industry in both domestic and international roles.

He currently serves as a Board member of Wellinks and previously served as a board member of Zipline Medical, BLDG Active and Nuo Therapeutics. Mr. Tozer also served as a founding executive and officer of The Alliance for Regenerative Medicine. He received a Bachelor of Commerce degree from Saint Mary’s University in Halifax, Nova Scotia and a Certified Management Accountant designation in Ontario, Canada.

Matt Zuga is co-founder of HighCape Partners, and brings more than 20 years of life sciences investment and banking experience. Mr. Zuga was formerly a Managing Director of Syngenta Ventures, an investment vehicle of Syngenta Corp. He was a founder and managing member of Red Abbey Venture Partners (RAVP), where he is currently a member of the Investment Committee.

His current board memberships include Aziyo Biologics and Alba Therapeutics (Co-Chairman). He has previously served as a Board member for Arginetix, Inc. and Board observer at Advanced BioHealing, Aegerion Pharmaceutical, Sirtris Pharmaceuticals and Stromedix, Inc. Prior to RAVP, Mr. Zuga was Head of Life Sciences investment banking at Legg Mason. Mr. Zuga received an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from The Ohio State University.